0      0


A CDMO Perspective Towards the Annex 1 Compliance


‐ May 9, 2023 5:15pm

A CDMO Perspective Towards the Annex 1 Compliance |

Implementation of the new Annex 1 poses a challenge for the (bio)pharmaceuticals industry, especially for small size companies. This session will present an insight how a CDMO could approach the final Annex 1 guidance, evaluate the text, address internal shortcomings and opportunities for improvements in a gap analysis, and plan to bridge the gaps towards the compliance, including risk assessments and contamination control strategy.


Speaker(s):

You must be logged in and own this session in order to post comments.